Growth Metrics

Lexaria Bioscience (LEXX) Income towards Parent Company (2017 - 2025)

Historic Income towards Parent Company for Lexaria Bioscience (LEXX) over the last 12 years, with Q4 2025 value amounting to -$1.6 million.

  • Lexaria Bioscience's Income towards Parent Company rose 4144.97% to -$1.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$10.8 million, marking a year-over-year decrease of 4747.72%. This contributed to the annual value of -$11.9 million for FY2025, which is 10697.15% down from last year.
  • Per Lexaria Bioscience's latest filing, its Income towards Parent Company stood at -$1.6 million for Q4 2025, which was up 4144.97% from -$2.7 million recorded in Q3 2025.
  • Lexaria Bioscience's 5-year Income towards Parent Company high stood at -$25000.0 for Q1 2021, and its period low was -$3.8 million during Q2 2025.
  • For the 5-year period, Lexaria Bioscience's Income towards Parent Company averaged around -$1.8 million, with its median value being -$1.7 million (2022).
  • Per our database at Business Quant, Lexaria Bioscience's Income towards Parent Company tumbled by 6688273.33% in 2021 and then surged by 4953.21% in 2024.
  • Quarter analysis of 5 years shows Lexaria Bioscience's Income towards Parent Company stood at -$2.0 million in 2021, then grew by 15.38% to -$1.7 million in 2022, then surged by 33.24% to -$1.1 million in 2023, then crashed by 137.73% to -$2.7 million in 2024, then surged by 41.45% to -$1.6 million in 2025.
  • Its Income towards Parent Company stands at -$1.6 million for Q4 2025, versus -$2.7 million for Q3 2025 and -$3.8 million for Q2 2025.